(Q37270950)

19 August 2017

1 reference

title

Evaluating the association between clozapine and venous thromboembolism (English)

1 reference

19 August 2017

main subject

venous thromboembolism

1 reference

based on heuristic

inferred from title

author name string

Christopher A Paciullo

series ordinal

1

1 reference

19 August 2017

publication date

1 October 2008

1 reference

American Journal of Health-System Pharmacy

19 August 2017

published in

1 reference

19 August 2017

volume

65

1 reference

19 August 2017

issue

19

1 reference

19 August 2017

page(s)

1825-1829

1 reference

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070638

Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070638

Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070638

Consensus development conference on antipsychotic drugs and obesity and diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070638

Myocarditis and cardiomyopathy associated with clozapine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070638

Fatal venous thromboembolism associated with antipsychotic therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070638

Association of venous thromboembolism and clozapine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070638

Clozapine and pulmonary embolus

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070638

Clozapine and sudden death

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070638

Massive pulmonary embolism in a young patient on clozapine therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070638

Antipsychotic drugs and venous thromboembolism

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070638

Psychotropic drugs and fatal pulmonary embolism

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070638

Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070638

Association of initial antipsychotic response to clozapine and long-term weight gain

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070638

Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070638

Functions of 5-HT2A receptor and its antagonists in the cardiovascular system

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070638

5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070638

The 5-hydroxytryptamine system of blood platelets: physiology and pathophysiology

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070638

The ralationship between changes in 5-HT induced platelet aggregation and clinical state in patients treated with fluphenazine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070638

The effects of neuroleptic drugs on 5-hydroxytryptamine induced platelet aggregation in schizophrenic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070638

In vitro effects of antipsychotics on human platelet adhesion and aggregation and plasma coagulation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070638

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070638

Clinical and epidemiological aspects in the antiphospholipid syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070638

Many faces of lupus anticoagulants

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070638

Antiphospholipid antibodies associated with clozapine treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070638

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070638

A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070638

Schizophrenia and increased risks of cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070638

Attenuation of Antipsychotic-Induced Weight Gain With Early Behavioral Intervention in Drug-Naive First-Episode Psychosis Patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070638

Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070638

31 March 2020

Identifiers

DOI

10.2146/AJHP070638

1 reference

19 August 2017

1 reference